Could ARNI have an Effect on LV Fibrosis and Inflammatory Parameters in an Experimental Autoimmune Myocarditis Model?

Creative Commons License

Duygu A., Gazi E., Deveci B., Arslan M., Öztopuz R. Ö., Adalı Y.

Eurasian Journal of Medical Investigation, vol.6, no.2, pp.190-197, 2022 (Peer-Reviewed Journal)


Objectives: The aim of this study is to investigate the efficacy of sacubitril-valsartan treatment in the early period of Experimental Autoimmune Myocarditis (EAM) model, under the perspective of fibrosis and inflammatory cytokines. Methods: The study was performed using 18 rats in three groups of EAM, Treatment, and control. EAM was induced by footpad injections of porcine cardiac myosin and Complete Freund’s Adjuvant (CFA). The EAM group was not given medical care. 20 mg/kg sacubitril-valsartan was given to Treatment group twice a day beginning from the 21st day to the 42nd day. Histopathological, biochemical and RT-PCR analyses were performed on the heart tissues taken after the 42nd day of sacrificing. Results: Significant congestion and fibrosis were observed in the EAM and Treatment groups. There was 50% less severe fibrosis,which is 3rd degree, in the Treatment group compared to EAM. Severe congestion rate was lower in the treatment group compared to EAM; with the percentage of 16,6% to 50%. Conclusion: In view of findings, the treatment of ARNI in acute autoimmune myocarditis may be promising on cardiac risk markers (cytokine, BNP values) and fibrosis parameters. Studies to be conducted in high-numbered groups will reveal more statistical significance. Keywords: Sacubitril/Valsartan, experimental myocarditis, heart failure, fibrosis, Wistar rat